Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer

References

• Abatzoglou I, Zois CE, Pouliliou S, Koukourakis MI. 2013. Establishment and validation of a method for multi-dose irradiation of cells in 96-well microplates. Biochem Biophys Res Commun. 431:456–459.
   PubMed Web of Science ®Google Scholar
• Campbell P, Irving CC, Lindahl R. 1989. Changes in aldehyde dehydrogenase during raturinary bladder carcinogenesis. Carcinogenesis. 10:2081–2087.
   PubMed Web of Science ®Google Scholar
• Cao Y, Guo WT, Tian S, He X, Wang XW, Liu X, Gu KL, Ma X, Huang D, Hu L, et al. 2015. miR-290/371-Mbd2-Myc circuit regulates glycolytic metabolism to promote pluripotency. EMBO J. 34:609–623.
   PubMed Web of Science ®Google Scholar
• Chai CY, Chen WT, Hung WC, Kang WY, Huang YC, Su YC, Yang CH. 2008. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol. 61:658–664.
   PubMed Web of Science ®Google Scholar
• Delaney G, Jacob S, Featherstone C, Barton M. 2005. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 104:1129–1137.
   PubMed Web of Science ®Google Scholar
• Eble JN, Sauter G, Epstein J L, Sesterhenn I, editors. 2004. WHO classification of classification of tumors of the urinary system and male genital organs. Lyon: IARCC Press.
   Google Scholar
• Falso MJ, Buchholz BA, White RW. 2012. Stem-like cells in bladder cancer cell lines with differential sensitivity to cisplatin. Anticancer Res. 32:733–738.
   PubMed Web of Science ®Google Scholar
• Helbig L, Koi L, Brüchner K, Gurtner K, Hess-Stumpp H, Unterschemmann K, Pruschy M, Baumann M, Yaromina A, Zips D. 2014. Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation. Int J Radiat Oncol Biol Phys. 88:159–166.
   PubMed Web of Science ®Google Scholar
• Holbrook JJ, Liljas A, Steindel SJ, Rossman MG. 1975. Lactate dehydrogenase. In: Boyer PD, editor. The enzymes, Vol. XI, 3rd ed. New York: Academic Press. pp. 191–292.
   Google Scholar
• Hoskin PJ, Sibtain A, Daley FM, Saunders MI, Wilson GD. 2004. The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiother Oncol. 72:159–168.
   PubMed Web of Science ®Google Scholar
• Jinesh GG, Willis DL, Kamat AM. 2014. Bladder cancer stem cells: Biological and therapeutic perspectives. Curr Stem Cell Res Ther. 9:89–101.
   PubMed Web of Science ®Google Scholar
• Kessler J, Hahnel A, Wichmann H, Rot S, Kappler M, Bache M, Vordermark D. 2010. HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: Effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer. 10:605.
   PubMed Web of Science ®Google Scholar
• Kinnaird A, Michelakis ED. 2015. Metabolic modulation of cancer: A new frontier with great translational potential. J Mol Med (Berl). 93:127–142.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Hamada J, Kobayashi C, Nakamura R, Suzuki Y, Kimata R, Nishimura T, Kitagawa T, Kunimoto M, Imura N, et al. 2005. Over expression of hypoxia-inducible factor-1alpha in renal and bladder cancer cells increases tumorigenic potency. J Urol. 173:1762–1766.
   PubMed Web of Science ®Google Scholar
• Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE. 2008. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys. 70:456–463.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL; TumourAngiogenesis Research Group. 2006a. Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway – a report of the Tumour Angiogenesis Research Group. J Clin Oncol. 24:4301–4308.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, et al. 2011. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 17:4892–4900.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E, Harris AL. 2006b. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol. 24:727–735.
   PubMed Web of Science ®Google Scholar
• Liao AC, Li CF, Shen KH, Chien LH, Huang HY, Wu TF. 2011. Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma. Pathology. 43:707–712.
   PubMed Web of Science ®Google Scholar
• Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al. 2011. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 17:211–215.
   PubMed Web of Science ®Google Scholar
• Lu QY, Zhang L, Yee JK, Go VW, Lee WN. 2015a. Metabolic consequences of LDHA inhibition by epigallocatechin gallate and oxamate in MIA PaCa-2 pancreatic cancer cells. Metabolomics. 11:71–80.
   PubMed Web of Science ®Google Scholar
• Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I, Bullen JW, Semenza GL. 2015b. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci USA. 112:E4600–609.
   PubMed Web of Science ®Google Scholar
• Masson N, Ratcliffe PJ. 2014. Hypoxia signaling pathways in cancer metabolism: The importance of co-selecting interconnected physiological pathways. Cancer Metab. 2:3.
   PubMedGoogle Scholar
• Munro NP, Sundaram SK, Weston PM, Fairley L, Harrison SC, Forman D, Chahal R. 2010. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys. 77:119–124.
   PubMed Web of Science ®Google Scholar
• Ord JJ, Agrawal S, Thamboo TP, Roberts I, Campo L, Turley H, Han C, Fawcett DW, Kulkarni RP, Cranston D, et al. 2007. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol. 178:677–682.
   PubMed Web of Science ®Google Scholar
• Rödel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R. 2002. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol. 20:3061–3071.
   PubMed Web of Science ®Google Scholar
• Rödel C, Weiss C, Sauer R. 2006. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 24:5536–5544.
   PubMed Web of Science ®Google Scholar
• Palit V, Phillips RM, Puri R, Shah T, Bibby MC. 2005. Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol Rep. 14:909–913.
   PubMed Web of Science ®Google Scholar
• Panteliadou M, Touloupidis S, Giatromanolaki A, Pistevou K, Kyrgias G, Tsoutsou P, Kalaitzis C, Koukourakis MI. 2011. Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC). Med Oncol. 28:1356–1362.
   PubMed Web of Science ®Google Scholar
• Panteliadou M, Giatromanolaki A, Touloupidis S, Destouni E, Tsoutsou PG, Pantelis P, Abatzoglou I, Sismanidou K, Koukourakis MI. 2012. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC). Urol Oncol. 30:813–820.
   PubMed Web of Science ®Google Scholar
• Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P. 1998. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 40:121–127.
   PubMed Web of Science ®Google Scholar
• Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. 1996. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 271:32529–32537.
   PubMed Web of Science ®Google Scholar
• Semenza GL. 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 29:625–634.
   PubMed Web of Science ®Google Scholar
• Semenza GL. 2016. Dynamic regulation of stem cell specification and maintenance by hypoxia-inducible factors. Mol Aspects Med. 48:15–23.
   Web of Science ®Google Scholar
• Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV. 1997. c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 94:6658–6663.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Gospodariwicz M, Wittekind C (editors). 2009. TNM classification of malignant tumors. UICC International Union Against Cancer. 7th ed. New York: Wiley-Blackwell. pp. 262–265.
   Google Scholar
• Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 157:411–421.
   PubMed Web of Science ®Google Scholar
• Tatokoro M, Koga F, Yoshida S, Kawakami S, Fujii Y, Neckers L, Kihara K. 2012. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer. 131:987–996.
   PubMed Web of Science ®Google Scholar
• Theodoropoulos VE, Lazaris AC, Kastriotis I, Spiliadi C, Theodoropoulos GE, Tsoukala V, Patsouris E, Sofras F. 2005. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. 95:425–431.
   PubMed Web of Science ®Google Scholar
• Warburg O. 1956. On the origin of cancer cells. Science. 123:309–314.
   PubMed Web of Science ®Google Scholar
• Yan H, Chen X, Zhang Q, Qin J, Li H, Liu C, Calhoun-Davis T, Coletta LD, Klostergaard J, Fokt I, et al. 2011. Drug-tolerant cancer cells show reduced tumor-initiating capacity: Depletion of CD44 cells and evidence for epigenetic mechanisms. PLoS One. 6:e24397.
   PubMed Web of Science ®Google Scholar
• Zachari MA, Chondrou PS, Pouliliou SE, Mitrakas AG, Abatzoglou I, Zois CE, Koukourakis MI. 2013. Evaluation of the alamarblue assay for adherent cell irradiation experiments. Dose Response. 12:246–258.
   PubMed Web of Science ®Google Scholar
• Zhao J, Du F, Luo Y, Shen G, Zheng F, Xu B. 2015. The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. Cancer Treat Rev. 41:623–633.
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, et al. 2010. Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 9:33.
   PubMed Web of Science ®Google Scholar